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Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia and dyslipidemia. The abnormalities in nutrient
metabolism and elevated inﬂammatory mediators resulting from DM lead to impairment of wound healing and vulnerability
to infection and foot ulcers. Diabetic lower limb ischemia often leads to limb necrosis. Lower extremity bypass surgery (LEBS)
is indicated to prevent limb loss in patients with critical leg ischemia. This study investigated the alteration of inﬂammatory and
endotheliumdysfunctionmarkersbeforeandafterLEBSinDMpatients.Twentyonetype2DMpatientswithLEBSwereincluded.
Blood was drawn before and at 1 day and 7 days after surgery in the patients. Plasma soluble cellular adhesion molecule levels and
blood leukocyte integrin expressions were measured. Also, plasma concentrations of endothelin-1 and nitric oxide were analyzed
to evaluate the vascular endothelial function. The results showed that there were no signiﬁcant diﬀerences in plasma cellular
adhesion molecules, endothelin-1 and nitric oxide levels, nor did any diﬀerences in leukocyte integrin expressions before and after
the operation. These results suggest that the eﬃcacy of LEBS on alleviating inﬂammatory reaction and improving endothelial
function in DM patients was not obvious.
Copyright © 2009 Pei-Hsuan Tsai et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Diabetes mellitus (DM) was the 4th leading cause of
death in Taiwan in 2007. Many diabetic patients have an
increased risk of atherosclerosis, cerebrovascular disease,
and peripheral vascular diseases [1]. The abnormalities in
nutrient metabolism and elevated inﬂammatory mediators
resulting from DM lead to impairment of wound healing
and vulnerability to infection and foot ulcers. Diabetic lower
limb ischemia caused by arterial occlusion is the most
common foot injury leads to lower extremity amputation in
DM patients [2]. Lower extremity bypass surgery (LEBS) is
indicated to prevent limb loss in patients with critical leg
ischemia. Previous studies revealed that a large reduction
in major amputation rates is associated with the increase of
LEBS [3, 4]. However, the eﬃcacy of LEBS on inﬂammatory
reaction in DM patients has not been evaluated and the
changes in inﬂammatory mediators before and after the
LEBS remain unknown.
Endothelial dysfunction accompanied by upregulated
inﬂammatory mediators is a major contributing factor to
the pathogenesis of diabetic vascular complications [5].
The injured vasculature endothelium promotes the expres-
sions of cellular adhesion molecules. Overexpressions of
cellular adhesion molecule facilitate leukocyte-endothelial
interactions which may aggravate inﬂammatory reaction
and tissue damage [6]. Previous study demonstrated that
increased levels of plasma soluble adhesion molecule occur
in type 2 patients [7]. Endothelin-1 (ET-1) is a potent
vasoconstrictor with mitogenic property. ET-1 stimulates
vascular smooth muscle cells proliferation, a major step in
the development of atherosclerosis [8]. Nitric oxide (NO) is
a vasodilator produced by endothelial cells. Other key roles
of NO include inhibiting platelet aggregation, smoothing2 Mediators of Inﬂammation
muscle cells proliferation, reducing monocyte adherence,
and so forth [9]. Previous study showed that at the onset
of diabetes, the release or response to NO is reduced [10].
Both ET-1 and NO are important mediators in maintaining
vascularfunctions.SinceLEBSincreasesbloodﬂowtotissues
that may carry oxygen and nutrients to the lower extremities
and improve the healing of the tissues [11], we hypothesized
that the inﬂammatory process and vascular dysfunction are
attenuated in DM patients undergoing LEBS. Therefore, the
aim of this study was to investigate whether reperfusion of
the lower extremities may improve the inﬂammation and
endothelial dysfunction in DM patients.
2.SubjectsandMethods
2.1. Subjects. This study was conducted from April to
December 2006 at Taipei Medical University-aﬃliated Wan
Fang Hospital. Twenty one type 2 DM patients with severe
diabetic lower limb ischemia and underwent LEBS were
enrolled in the experimental group. The diabetes duration
was 6–30 years, with a mean of 18.2 years. Insulin and com-
binedtherapyifnecessarywereusedtocontrolbloodglucose
to within a range of 106–259mg/dL. No leg infection was
observed in LEBS patients, possibly because the operation
was successful and the antibiotics used after the surgery. The
protocol was approved by the hospital ethics committee, and
all the patients gave their informed written consent prior to
their participation in this study.
2.2. Blood Sampling. Blood samples were taken from each
patient before and at 1 day and 7 days after the LEBS
in DM patients. Ten milliliters of blood were drawn after
12 hours of fasting, placed in tubes containing ethylene
diaminetetraacetic acid. Fresh blood samples were collected
for the analysis of leukocyte CD11a/CD18 and CD11b/CD18
expressions. Plasma samples obtained from whole blood
centrifugation at 3000rpm for 10 minutes were stored at
−80
◦C until further analysis.
2.3. Measurements and Analytical Procedures. Total choles-
terol, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, triglyceride, and creatinine were
analyzed by an autoanalyser (Hitachi 7170, Tokyo, Japan).
Blood HbA1C was measured using a commercial kit (Helena
BioSciences,sunderland,UK).Proceduresfollowedtheman-
ufacturer instructions.
2.4. Measurements of Plasma ET-1, NO, sICAM-1, sVCAM-1,
and C-reactive Protein Concentrations. Concentrations of
plasma ET-1, soluble intracellular adhesion molecule
(sICAM)-1, soluble vascular cell adhesion molecule
(sVCAM)-1, and C-reactive protein (CRP) were measured
using commercial enzyme-linked immunosorbent assay
(ELISA) kits (R&D systems, Minneapolis, MN, USA).
Concentrations of NO2
−/NO3
− were determined with a
commercial kit (R&D systems). Procedures followed the
manufacturer instructions. The minimum detectable dose
of ET-1, sICAM-1, sVCAM-1, and CRP were 0.064pg/mL,
Table 1: Characteristics of the subjects.
Diabetic patients
Age (yr) 70.7 ±9.0
Gender (M/F) 10/11
Blood glucose (mg/dL) 175.9 ±59.5
HbA1C (%) 8.7 ±2.3
Total cholesterol (mg/dL) 152.9 ±35.6
HDL-C (mg/dL) 32.7 ±13.1
LDL-C (mg/dL) 86.0 ±33.2
Triglyceride (mg/dL) 145.8 ±81.6
Creatinine (mg/dL) 3.70 ±3.44
Data are expressed as the mean ± SD. Abbreviations: HbA1C: Hemoglobin
A1C; HDL-C: High-density lipoprotein-cholesterol; LDL-C: Low-density
lipoprotein-cholesterol.




2.5. Analysis of Lymphocyte CD11a/CD18 and Polymor-
phoneuclear Neutrophil CD11b/CD18 Expressions. One hun-
dred microliters of fresh blood was incubated with 10uL
ﬂuorescent isothiocynate (FITC)-conjugated mouse mono-
clonal antihuman CD11a and phycoerthrin (PE)-conjugated
mouse monoclonal antihuman CD18 (Serotec, Oxford, UK)
for 15 minutes at 4◦C. The proportions of CD11a/CD18
expressed on lymphocytes were analyzed by ﬂow cytometry
(Coulter, Miami, FL). The results are presented as a percent-
age of CD11a-presenting cells in 1 × 105 lymphocytes. To
measure CD11b/CD18 expressions on polymorphoneuclear
neutrophils (PMNs), FITC-conjugated mouse monoclonal
antihuman CD11b and PE-conjugated mouse monoclonal
antihuman CD18 (Serotec) were added into 100μLo f
fresh blood. The results are presented as a percentage of
CD11b/CD18expressionin1×105 PMNs.Lymphocytesand
PMNs were gated on the basis of the forward scatter and
side scatter proﬁles and were analyzed for the expressions of
CD11a/CD18 and CD11b/CD18, respectively.
2.6. Statistical Analysis. Data are presented as mean ± SD.
All statistical analyses were performed using SAS software
package. The diﬀerences among diﬀerent time points were
determined by one-way analysis of variance. P < .05 was
considered statistically signiﬁcant.
3. Results
The characteristics of the subjects were presented in Table 1.
There were no signiﬁcant diﬀerences in plasma ET-1 and NO
levels (Table 2), nor did any diﬀerences in plasma sVCAM,
sICAM, and CRP levels before and after the operation
(Table 3). Also, leukocyte CD11a/CD18 and CD11b/CD18
expressions before and after the operation did not diﬀer in
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Table 2: Plasma endothelin (ET)-1 and nitric oxide (NO) concen-
trations before and after the surgery.
Days ET-1 NO
(pg/mL) (umol/L)
02 .2 ±0.53 .5 ±1.7
12 .0 ±0.22 .5 ±0.7
72 .2 ±0.43 .4 ±1.9
Data are expressed as the mean ± SD.
Table 3: Plasma soluble intercellular adhesion molecule (sICAM),
soluble vascular cell adhesion molecule (sVCAM), and C-reactive
protein (CRP) concentrations before and after the surgery.
Days sVCAM sICAM CRP
(ng/mL) (ug/mL)
0 1406.2 ±839.7 344.3 ±121.85 3 .4 ±46.7
1 1415.9 ±722.6 332.3 ±112.16 4 .6 ±54.9
7 1224.9 ±632.8 398.5 ±126.94 8 .3 ±45.7
Data are expressed as the mean ± SD.
Table 4: Expressions of lymphocyte CD11a/CD18 and neutrophil
CD11b/CD18 before and after the surgery.
Days CD11a/CD18 CD11b/CD18
(%)
04 8 .2 ±18.03 .1 ±2.0
14 2 .4 ±12.02 .9 ±1.3
74 3 .5 ±12.33 .5 ±1.1
Data are expressed as the mean ± SD.
4. Discussion
This study evaluated an LEBS-induced change in inﬂam-
matory response and endothelial function. We found that
compared with the preoperative condition, the mediators
related to inﬂammation and vascular function did not
change in type 2 DM patients at early and late stages after
LEBS.
Diabetic patients often have endothelial dysfunction
and releasing of endothelins is partly responsible for this.
Previous report found that plasma ET-1 levels are enhanced
in patients with poor glycemic control [12] and ET-1 levels
were even higher in DM patients complicated with vascular
diseases [13]. A study performed by Schneider et al. [14]
found that diabetic patients taking angiotensin converting
enzymeinhibitorshadlowerplasmaET-1levelsthanpatients
without, indicating that medical intervention did improve
ET-1 levels. In addition to ET-1, NO is also an important
regulatory determinant of vascular tissue homeostasis. NO
plays a protective role by suppressing abnormal proliferation
of vascular smooth muscle following various vascular inter-
ventions such as bypass grafting [15]. In this study, we did
not observe diﬀerences in plasma ET-1 and NO levels before
and 1 or 7 days after surgery. This result may indicate that
LEBS performed in this study did not, at least in the short
run, improve endothelial function in DM patients.
CRP is an inﬂammatory marker. CRP levels were cor-
related with peripheral artery disease severity in patients
undergoing LEBS [16]. ICAM-1 and VCAM-1 are adhesion
proteins synthesized by endothelial cells. Their expres-
sions greatly increase after stimulation by proinﬂammatory
cytokines [17]. Previous study showed that tissue ICAM-
1 levels were positively correlated with blood glucose levels
[18]. Adhesive interactions between leukocytes and endothe-
lial cells are involved in inﬂammatory or immunologic
response mechanisms. Adhesion molecules on endothelial
cells are the ligands of integrins on leukocytes. CD11a
and CD11b/CD18 are members of the leukocyte adhe-
sion molecules β2 integrin. CD11a/CD18 are exclusively
expressed on leukocytes and CD11b/CD18 are abundant
in PMNs [19]. In this study, we analyzed lymphocyte
CD11a/CD18 because the function of T-lymphocyte sub-
sets is important on inﬂuencing the type of immu-
nity and the inﬂammatory response to infection [20].
CD11b/CD18 expressed by neutrophil is important in medi-
ating neutrophil-endothelial cell interactions and binding to
adhesion molecule on the surface of vascular endothelial
cells [21, 22]. Previous reports revealed that neutrophil
CD11b/CD18 increases in infected patients and is correlated
with microvascular dysfunction [23]. In this study, we did
not observe the diﬀerence in leukocyte CD11a/CD18 and
CD11b/CD18 expressions before and after the operation.
This result was consistent with plasma sVCAM-1, sICAM-
1, and CRP levels that these inﬂammatory proteins did not
change after LEBS. These ﬁndings indicate that compared
with preoperative state, LEBS did not attenuate inﬂamma-
tory reaction in DM patients. Surgery and trauma induce a
generalized state of inﬂammation. Although LEBS increases
bloodﬂowtotheperipheraltissues,surgicalinjurystimulates
the production of endogenous inﬂammatory mediators.
Besides, reperfusion of the ischemic tissues may also result in
exaggerated inﬂammatory response [24, 25], this may make
the alteration of inﬂammatory mediators not so obvious
before and after the surgery.
In conclusion, this is a pilot study to demonstrate that
compared with the preoperative condition, no diﬀerences
in plasma concentrations of ET-1, NO, and inﬂammatory
mediators were observed in DM patients after LEBS. This
result suggests that the eﬀect of LEBS on alleviating the
inﬂammatory reaction and improving endothelial function
in DM patients was not obvious.
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